Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Equivalents (2016 - 2024)

Historic Cash & Equivalents for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $182.3 million.

  • KalVista Pharmaceuticals' Cash & Equivalents changed N/A to $182.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $182.3 million, marking a year-over-year change of. This contributed to the annual value of $31.8 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Cash & Equivalents stood at $182.3 million.
  • KalVista Pharmaceuticals' Cash & Equivalents' 5-year high stood at $182.3 million during Q4 2024, with a 5-year trough of $15.8 million in Q2 2020.
  • Moreover, its 4-year median value for Cash & Equivalents was $27.4 million (2024), whereas its average is $42.0 million.
  • In the last 5 years, KalVista Pharmaceuticals' Cash & Equivalents crashed by 6696.25% in 2020 and then crashed by 477.03% in 2021.
  • Quarter analysis of 4 years shows KalVista Pharmaceuticals' Cash & Equivalents stood at $16.2 million in 2020, then increased by 9.6% to $17.7 million in 2021, then surged by 225.3% to $57.7 million in 2023, then surged by 216.18% to $182.3 million in 2024.
  • Its Cash & Equivalents stands at $182.3 million for Q4 2024, versus $41.6 million for Q4 2024 and $31.8 million for Q3 2024.